Gu Chao, Xie Li, Li Bowen, Zhang Lu, Li Fengyuan, Wang Weizhi, Su Jiang, Xu Zekuan
Department of General Surgery, The First Affiliated Hospital, Nanjing Medical University, Nanjing, China.
Department of General Surgery, The Affiliated Suzhou Hospital, Nanjing Medical University, Suzhou, China.
Clin Med Insights Oncol. 2022 Jun 24;16:11795549221104440. doi: 10.1177/11795549221104440. eCollection 2022.
Abnormal glycosylation of proteins has been identified in almost all types of cancers and is closely related to the cancer progression, metastasis, and survival of cancer patients. This study was to explore the values of serum tumor abnormal protein (TAP), an abnormal glycochain protein, in the diagnosis and prognosis of gastric cancer (GC).
A total of 335 GC patients were included as the study group, and another 335 subjects served as the control group. Tumor abnormal protein expression was compared between the 2 groups. Correlation analysis was used to assess the correlations of TAP with clinicopathological factors. Gastric cancer patients were divided into training set and test set at a ratio of 2:1. Univariate and multivariate Cox regression analyses in training set were used to evaluate the prognostic significance of TAP in GC patients and explore the independent risk factors for overall survival (OS) and disease-free survival (DFS) to establish a prognostic model, followed by testing of the model. According to the median of TAP, 335 GC patients were divided into 2 groups to plot the survival curves of OS and DFS.
Tumor abnormal protein expression in the study group was significantly higher than in the control group. Taking the best cut-off value of TAP (110.128 μm) as the diagnostic criteria for GC, the sensitivity and specificity of TAP were 83.58% and 97.61%, respectively, and the area under the receiver operating characteristics (ROC) curve was 0.935, which was not inferior to computed tomography (CT). Tumor abnormal protein expression was an independent risk factor for OS and DFS. The prognostic predictive value of TAP was better than that of pathological stage in GC patients. The model with TAP was effective in predicting prognosis.
Tumor abnormal protein is an effective indicator for early screening and prognostic evaluation of GC and can also assist the clinical diagnosis and treatment of GC.
几乎在所有类型的癌症中都发现了蛋白质糖基化异常,其与癌症进展、转移及癌症患者的生存密切相关。本研究旨在探讨血清肿瘤异常蛋白(TAP),一种异常糖链蛋白,在胃癌(GC)诊断及预后中的价值。
共纳入335例GC患者作为研究组,另335例受试者作为对照组。比较两组间肿瘤异常蛋白表达情况。采用相关性分析评估TAP与临床病理因素的相关性。将胃癌患者按2:1的比例分为训练集和测试集。在训练集中采用单因素和多因素Cox回归分析评估TAP在GC患者中的预后意义,并探索总生存(OS)和无病生存(DFS)的独立危险因素以建立预后模型,随后对模型进行验证。根据TAP的中位数,将335例GC患者分为两组,绘制OS和DFS的生存曲线。
研究组肿瘤异常蛋白表达显著高于对照组。以TAP的最佳截断值(110.128μm)作为GC的诊断标准,TAP的敏感性和特异性分别为83.58%和97.61%,受试者操作特征(ROC)曲线下面积为0.935,不低于计算机断层扫描(CT)。肿瘤异常蛋白表达是OS和DFS的独立危险因素。TAP在GC患者中的预后预测价值优于病理分期。含TAP的模型在预测预后方面有效。
肿瘤异常蛋白是GC早期筛查和预后评估的有效指标,也可辅助GC的临床诊断和治疗。